Brachytherapy · 2025
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Virbel Guillaume, Ka Kanta, Escande Alexandre, Mortier Laurent, Barthoulot Mael, Liem Xavier, Mirabel Xavier, Lartigau Eric F, Cordoba Abel
Аннотация
INTRODUCTION: Nonmelanoma skin cancer (NMSC), encompassing basal and squamous cell carcinomas, is among the most common malignancies worldwide. While surgery is the standard for early-stage lesions, it can be disfiguring for periorificial facial tumors.
OBJECTIVE: To assess local and regional control, as well as toxicity outcomes, in patients with facial NMSC treated by brachytherapy at a comprehensive cancer center.
MATERIALS AND METHODS: A total of 155 patients were included. Of these, 115 had squamous cell carcinoma and 34 had basal cell carcinoma. The lip was the most frequent site (103 cases), followed by the nose (49 cases). Brachytherapy was exclusive in 128 patients and adjuvant in 27.
RESULTS: At 24 months, local and locoregional control rates were 93.9% (95% CI: 89.4-98.5%) and 90.3% (95% CI: 84.8-96.1%) respectively. No grade ≥3 late toxicity was observed.
CONCLUSION: Brachytherapy is a safe and effective organ-preserving option for facial NMSC, particularly in patients with anatomically complex lesions or contraindications to surgery.
OBJECTIVE: To assess local and regional control, as well as toxicity outcomes, in patients with facial NMSC treated by brachytherapy at a comprehensive cancer center.
MATERIALS AND METHODS: A total of 155 patients were included. Of these, 115 had squamous cell carcinoma and 34 had basal cell carcinoma. The lip was the most frequent site (103 cases), followed by the nose (49 cases). Brachytherapy was exclusive in 128 patients and adjuvant in 27.
RESULTS: At 24 months, local and locoregional control rates were 93.9% (95% CI: 89.4-98.5%) and 90.3% (95% CI: 84.8-96.1%) respectively. No grade ≥3 late toxicity was observed.
CONCLUSION: Brachytherapy is a safe and effective organ-preserving option for facial NMSC, particularly in patients with anatomically complex lesions or contraindications to surgery.